SGLT2 Inhibitors Cut Kidney Events in Nephrotic Proteinuria
A study found that SGLT2 inhibitors significantly reduce the risk of major adverse kidney events in adults with type 2 diabetes and nephrotic-range proteinuria. Compared to DPP-4 inhibitors, SGLT2 inhibitors were associated with lower rates of end-stage kidney disease and all-cause mortality. These findings support the kidney-protective potential of SGLT2 inhibitors in high-risk diabetic patients.
- ▪Initiating SGLT2 inhibitors was linked to a 25% lower risk for major adverse kidney events compared to DPP-4 inhibitors.
- ▪Participants using SGLT2 inhibitors had a lower risk for end-stage kidney disease and all-cause mortality.
- ▪The study included 2102 participants with a mean age of approximately 61 years.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Among adults with type 2 diabetes (T2D) and nephrotic-range proteinuria, an extremely high-risk phenotype, initiating SGLT2 inhibitors instead of DPP-4 inhibitors was associated with lower long-term risks for major adverse kidney events (MAKEs), end-stage kidney disease requiring dialysis, and death from any cause.METHODOLOGY:Although SGLT2 inhibitors have demonstrated clear cardiorenal benefits in major randomized trials, it remains uncertain whether those benefits apply across the full spectrum of diabetic kidney disease — especially in patients with nephrotic-range proteinuria who were underrepresented in trials.Researchers conducted a retrospective cohort study using a new-user, active-comparator target trial emulation design to compare the effect of initiating SGLT2…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
